R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
2001-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of R115777 in treating patients who have
refractory or recurrent acute leukemia or chronic myelogenous leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
University of Maryland Greenebaum Cancer Center University of Maryland, Baltimore